US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Nektar Says Eli Lilly Botched Autoimmune Drug Trials

By Ayden Crosby · August 7, 2023, 7:47 PM EDT

Nektar Therapeutics is accusing Eli Lilly of butchering and delaying clinical trials for a new autoimmune-disease drug the two companies agreed to develop together, claiming the pharma giant ruined the drug's...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Nektar Therapeutics v. Eli Lilly & Co

Case Number

3:23-cv-03943

Court

California Northern

Nature of Suit

Contract: Other

Date Filed

August 07, 2023

Featured Stories

Medical Marijuana Industry Grapples With DEA's New Role No Photo Available

Sam Reisman

After years of allowing the state-sanctioned medical marijuana industry to operate without interference, the U.S. Drug Enforcement Adm... (more story)

What Kaiser's D&O Win Means For 'Return Of Funds' Fights No Photo Available

Abraham Gross

A California federal judge's ruling that the Kaiser Foundation Health Plan was not automatically prohibited from claiming coverage for... (more story)

Merck Drug Price Row Loss, $56M Biotech Verdict And More No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at a D.C. federal court's rejection of Merck's challenge to the Medicare drug price negotiation prog... (more story)